Rosemary F. Zhang

Statistics

Publications

Citations

236

H-Index

Active since

2005

Affiliations

Bristol-Myers Squibb (United States)(Current)

Rosemary F. Zhang is an author at Bristol-Myers Squibb (United States) specializing in drug discovery, medicinal chemistry, and molecular pharmacology.

Publications per year

2005–2019

Publications

5-Cyanopyrimidine Derivatives as a Novel Class of Potent, Selective, and Orally Active Inhibitors of p38α MAP Kinase

Chunjian Liu, Stephen T. Wrobleski, James C. Lin et al. · Journal of Medicinal Chemistry · 2005 · 70 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14

Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-<i>N</i>-propylpyrrolo[1,2-<i>f</i>][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases

Chunjian Liu, James C. Lin, Stephen T. Wrobleski et al. · Journal of Medicinal Chemistry · 2010 · 57 citations · Full text

Medicine, Medicinal Chemistry, Pharmacokinetics +14

Benzothiazole based inhibitors of p38α MAP kinase

Chunjian Liu, James C. Lin, Sidney Pitt et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 51 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +8

Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors

James J.‐W. Duan, Zhonghui Lu, Bin Jiang et al. · Bioorganic & Medicinal Chemistry Letters · 2014 · 30 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors

John Hynes, Wu Hong, James Kempson et al. · Bioorganic & Medicinal Chemistry Letters · 2017 · 14 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

1–5 of 6